Business

Mass. Movers

Vertex reports progress on CF treatment

The biotech’s new treatment may help thousands.
The Boston Globe/File 2006
The biotech’s new treatment may help thousands.

Vertex Pharmaceuticals’ shares soared after the Cambridge biotech released positive clinical data on an experimental treatment for cystic fibrosis. Vertex said a midstage study of its VX-661 drug candidate in combination with its approved cystic fibrosis drug Kalydeco “showed statistically significant improvements in lung function” among adults with two copies of a common cystic fibrosis regulator gene mutation. The disease causes mucus to build up in the lungs and digestive tract.